lapatinib

Metabolite details

Identifier: BCFGMOOMADDAQU-UHFFFAOYSA-N
InChI Key: BCFGMOOMADDAQU-UHFFFAOYSA-N
IUPAC name: N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine
Preferred name: lapatinib
INN name: —
Synonym: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
ChEBI: CHEBI:49603

R-HSA-1227986 - Signaling by ERBB2
R-HSA-1227990 - Signaling by ERBB2 in Cancer
R-HSA-1236382 - Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
R-HSA-162582 - Signal Transduction
R-HSA-1643685 - Disease
R-HSA-1643713 - Signaling by EGFR in Cancer
R-HSA-5637815 - Signaling by Ligand-Responsive EGFR Variants in Cancer
R-HSA-5663202 - Diseases of signal transduction by growth factor receptors and second messengers
R-HSA-9006934 - Signaling by Receptor Tyrosine Kinases
R-HSA-9634285 - Constitutive Signaling by Overexpressed ERBB2
R-HSA-9652282 - Drug-mediated inhibition of ERBB2 signaling
R-HSA-9664565 - Signaling by ERBB2 KD Mutants
R-HSA-9665230 - Drug resistance in ERBB2 KD mutants
R-HSA-9665251 - Resistance of ERBB2 KD mutants to lapatinib
R-HSA-9665348 - Signaling by ERBB2 ECD mutants
R-HSA-9665686 - Signaling by ERBB2 TMD/JMD mutants